Recognition that CCK, acting through CCK1R, is one of the most prominent and earliest recognized physiologic regulators of appetite (1) stimulated extensive pharmaceutical efforts to develop full agonists targeting this receptor as potential treatments for obesity. The gene discussed is CCK; the disease is obesity due to melanocortin 4 receptor deficiency.